Cutaneous squamous cell carcinoma (CSCC) management is evolving, with updated NCCN guidelines emphasizing more precise risk stratification, deeper biopsies, and earlier integration of systemic immunotherapy, including neoadjuvant and adjuvant PD-1–based therapies. Multidisciplinary care, patient-centered treatment decisions, and emerging research on combination strategies, intralesional therapy, and biomarkers are shaping a new era of personalized, immune-driven CSCC care.
A panelist outlines how advances in molecular diagnostics, particularly NGS, are refining follicular lymphoma classification and informing selective therapeutic decisions—most notably the use of EZH2-targeted therapy. He describes how emerging agents such as CD19-directed therapies, bispecific antibodies, and potent new combinations are reshaping treatment sequencing, which must also account for antigen preservation, prior response durability, and individual patient factors. Together, these updates reflect a rapidly evolving landscape that demands personalized, forward-thinking treatment planning.
